Health policy: Addressing conflicts of interest of public speakers at advisory committee meetings

Nature Reviews Clinical Oncology

Volumn 13, Issue 5, 2016, Pages 267-268

  McCoy, Matthew S ^a   Emanuel, Ezekiel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT; DOCTOR PATIENT RELATION; FINANCIAL MANAGEMENT; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL SERVICE; MEDICAL SOCIETY; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; PUBLICATION; REVIEW; ADVISORY COMMITTEE; CONFLICT OF INTEREST; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY;

ADVISORY COMMITTEES; CONFLICT OF INTEREST; HEALTH POLICY; HUMANS; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84966318373     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.54     Document Type: Review

References (11)

1. Hunter, N. L., O'Callaghan, K. M., Califf, R. M. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA 314, 2499-2500 (2015).
2. Agency for Healthcare Research and Quality. How to get involved in the Effective Health Care Program: a concise guide for stakeholders. [online], http://effectivehealthcare.ahrq.gov/index.cfm/tools-and-resources/how-to-get-involved-in-the-effective-health-care-program/(2016).
3. Ahmed, S. M., Palermo, A. G. Community engagement in research: frameworks for education and peer review. Am. J. Public Health 100, 1380-1387 (2010).
4. Patient-Centered Outcomes Research Institute. What we mean by engagement. [online], http://www.pcori. org/funding-opportunities/what-we-mean-engagement (2015).
5. Abola, M. V., Prasad, V. Characteristics and conflicts of public speakers at meetings of the Oncologic Drugs Advisory Committee to the US Food And Drug Administration. JAMA Intern. Med. 176, 389-391 (2016).
6. Katz, D., Caplan, A. L., Merz, J. F. All gifts large and small. Am. J. Bioeth. 3, 39-46 (2003).
7. Davis, C., Abraham, J. Unhealthy Pharmaceutical Regulation: Innovation, Politics and Promissory Science Ch. 4 (Springer, 2013).
8. Federal Register. AstraZeneca Pharmaceuticals LP; withdrawal of approval of a new drug application for IRESSA. [online], https://www.federalregister.gov/articles/2012/04/25/2012-9944/astrazeneca-pharmaceuticals-lp-withdrawal-of-approval-of-a-new-drug-application-for-iressa (2012).
9. Marrs, L., Kumar, S. V., Perry, S., Richards, A. How health nonprofits handle contributions from medical companies. The Chronicle of Philanthropy [online], https://philanthropy.com/article/How-Health-Nonprofits-Handle/160015/(2010).
10. U.S. Food and Drug Administration. Advisory Committee guidance documents. [online], http://www.fda.gov/RegulatoryInformation/Guidances/ucm122045.htm (2014).
11. Thompson, D. F. The challenge of conflict of interest in medicine. Z. Evid. Fortbild. Qual. Gesundhwes 103, 136-140 (2009).